Skip to main content
. 2016 Nov 21;31(5):e22099. doi: 10.1002/jcla.22099

Table 2.

Current CVs of each group categorized by control material vendors for HbA1c from 2012 to 2016 (%)a

Manufacturer of control materials Percentage of labs % (N/total) Mass fraction Current CVs
Median IQRb Median IQRb
2012
Bio‐Rad 45.1 (138/306) 5.70 0.32 2.12 1.93
TOSOH 10.9 (33/306) 5.52 0.29 1.30 0.77
Roche 11.9 (36/306) 6.20 0.88 4.10 2.86
RANDOX 5.5 (17/306) 5.68 0.35 4.02 2.97
In‐house preparation 5.1 (16/306) 6.10 0.67 2.16 1.91
Others 21.5 (66/306) 5.52 0.67 3.00 3.17
2013
Bio‐Rad 51.6 (158/306) 5.61 0.21 2.00 1.09
TOSOH 12.0 (37/306) 5.53 0.45 1.11 0.94
Roche 10.0 (31/306) 6.10 0.60 3.27 2.19
RANDOX 4.8 (14/306) 5.63 0.34 4.21 5.39
In‐house preparation 2.4 (7/306) 5.90 0.89 1.44 1.25
Others 19.2 (58/306) 5.43 0.56 2.71 3.06
2014
Bio‐Rad 54.6 (167/306) 5.34 0.22 2.01 1.36
TOSOH 14.9 (45/306) 5.56 0.39 1.49 1.00
Roche 7.1 (22/306) 6.30 0.84 3.32 2.37
RANDOX 4.3 (13/306) 5.38 0.55 2.00 2.12
In‐house preparation 2.8 (9/306) 5.80 1.23 2.39 2.58
Others 16.3 (50/306) 5.37 0.45 1.79 1.58
2015
Bio‐Rad 54.5 (166/306) 5.33 0.21 1.98 1.46
TOSOH 15.1 (46/306) 5.16 0.79 1.26 1.08
Roche 6.1 (19/306) 5.70 0.45 2.59 1.97
RANDOX 3.6 (11/306) 5.56 0.54 2.14 3.22
In‐house preparation 5.4 (16/306) 5.67 1.09 1.82 1.41
Others 15.4 (47/306) 5.39 0.32 1.64 2.66
2016
Bio‐Rad 56.5 (173/306) 5.39 0.23 1.76 1.51
TOSOH 15.2 (47/306) 5.09 0.20 1.12 1.18
Roche 5.5 (17/306) 5.79 0.36 2.54 1.23
RANDOX 4.2 (13/306) 5.50 0.61 1.97 1.98
In‐house preparation 5.9 (18/306) 5.72 1.15 1.52 1.27
Others 12.7 (39/306) 5.40 0.41 1.25 1.69
a

The subgroup analyses of the current CVs and mass fraction were both for level 1.

b

Interquartile range (IQR) is equal to the difference between the upper and lower quartiles, IQR=Q3‐Q1.